December 09, 2025 01:45 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Race against time! Indian Navy sends four more warships to Cyclone Ditwah-hit Sri Lanka | $2 billion mega deal! HD Hyundai to build shipyard in Tamil Nadu — a game changer for India | After 8 years of legal drama, Malayalam actor Dileep acquitted in 2017 rape case — what really happened? | Centre imposes temporary fare caps as ticket prices defy gravity amid IndiGo meltdown | 'Action is coming': Aviation Minister blames IndiGo for countrywide air travel chaos | In front of Putin, PM Modi makes bold statement on Russia-Ukraine war: ‘India is not neutral, we side with peace!’ | Rupee weakens following RBI repo rate cut | RBI slashes repo rate by 25 basis points — big relief coming for borrowers! | 'Mamata fooled Muslims': Humayun Kabir explodes after TMC suspends him over 'Babri Masjid-style mosque' demand; announces new party | Mosque in the middle of Kolkata airport? Centre confirms flight risks, BJP fires at Mamata
Sputnik V
Wallpaper Cave

Argentine scientists say one dose of Russia's Sputnik V develops high immune response

| @indiablooms | Apr 14, 2021, at 02:38 pm

Moscow/Sputnik: The Russian COVID-19 vaccine Sputnik V prompts a high immune response even with a single dose, a study by Argentine scientists and cited by the country's government on Tuesday, has shown.

Last month, the Argentine government decided to delay second doses of vaccines in a bid to offset the shortages in drugs against the COVID-19 disease across the world.

"A global analysis of the immune response induced by the Sputnik V vaccine, in which 288 individuals participated, indicates that 94% showed the presence of specific antibodies after receiving a single dose," the government said, citing the study.

Notably, 61 participants were previously infected with COVID-19. According to the study, they had 4.6 times more antibodies after the Russian vaccine shot than the rest of the group.

The study also revealed that 96 percent of people under 60 developed antibodies within 21 days after getting vaccinated. The rate stands at 89 percent among those aged over 60.
After two doses of Sputnik V, 100 percent of immunized people have antibodies, the study also noted.

Sputnik V has so far been approved for use in 60 states across the world. According to phase 3 trial results published in The Lancet medical journal, the vaccine has 91.6 percent efficacy against symptomatic COVID-19.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.